AU709149B2 - Method for treating and inhibiting gastric and duodenal ulcers - Google Patents

Method for treating and inhibiting gastric and duodenal ulcers Download PDF

Info

Publication number
AU709149B2
AU709149B2 AU19323/95A AU1932395A AU709149B2 AU 709149 B2 AU709149 B2 AU 709149B2 AU 19323/95 A AU19323/95 A AU 19323/95A AU 1932395 A AU1932395 A AU 1932395A AU 709149 B2 AU709149 B2 AU 709149B2
Authority
AU
Australia
Prior art keywords
oligosaccharide
stomach
gal
group
duodenum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19323/95A
Other languages
English (en)
Other versions
AU1932395A (en
Inventor
Dennis H Langer
Edward J Mcguire
Stephen Roth
Paul M Simon
David A Zopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neose Technologies Inc
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of AU1932395A publication Critical patent/AU1932395A/en
Assigned to NEOSE TECHNOLOGIES, INC. reassignment NEOSE TECHNOLOGIES, INC. Amend patent request/document other than specification (104) Assignors: NEOSE PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU709149B2 publication Critical patent/AU709149B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU19323/95A 1994-03-02 1995-03-02 Method for treating and inhibiting gastric and duodenal ulcers Ceased AU709149B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20451594A 1994-03-02 1994-03-02
US204515 1994-03-02
PCT/US1995/002388 WO1995023605A1 (fr) 1994-03-02 1995-03-02 Procede de traitement et d'inhibition des ulceres gastriques et duodenaux

Publications (2)

Publication Number Publication Date
AU1932395A AU1932395A (en) 1995-09-18
AU709149B2 true AU709149B2 (en) 1999-08-19

Family

ID=22758224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19323/95A Ceased AU709149B2 (en) 1994-03-02 1995-03-02 Method for treating and inhibiting gastric and duodenal ulcers

Country Status (5)

Country Link
EP (1) EP0749314A4 (fr)
JP (1) JP3179108B2 (fr)
AU (1) AU709149B2 (fr)
CA (1) CA2183329A1 (fr)
WO (1) WO1995023605A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
KR20000010732A (ko) * 1996-05-03 2000-02-25 스티븐 로쓰 시알릴올리고당의 비스무트염 및 이를 사용한위궤양 및 십이지장궤양 치료 및 억제 방법
US8003782B1 (en) 1999-02-01 2011-08-23 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
SE9901007D0 (sv) * 1999-03-19 1999-03-19 Thomas Boren Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
NL2007931C2 (en) * 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
WO2020060260A1 (fr) * 2018-09-20 2020-03-26 가톨릭대학교 산학협력단 Composite polymère pour la reconnaissance de l'helicobacter pylori et composition pour la thérapie photodynamique la comprenant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
JPH0436294A (ja) * 1990-06-01 1992-02-06 Snow Brand Milk Prod Co Ltd 牛乳由来の新規なガングリオシド及びその製造法
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5254676A (en) * 1991-11-22 1993-10-19 E. I. Du Pont De Nemours And Company Oligosaccharide inhibitors for influenza virus
EP0630251A1 (fr) * 1992-03-19 1994-12-28 University Of British Columbia Procede et composition permettant de supprimer les effets secondaires de medicaments anti-inflammatoires
WO1993023055A1 (fr) * 1992-05-15 1993-11-25 The University Of British Columbia Glucosamine d'acetyle-n en tant qu'agent gastroprotecteur
AU4993893A (en) * 1992-07-31 1994-03-03 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers

Also Published As

Publication number Publication date
CA2183329A1 (fr) 1995-09-08
AU1932395A (en) 1995-09-18
WO1995023605A1 (fr) 1995-09-08
JP3179108B2 (ja) 2001-06-25
JPH09509931A (ja) 1997-10-07
EP0749314A1 (fr) 1996-12-27
EP0749314A4 (fr) 2002-09-18

Similar Documents

Publication Publication Date Title
US5753630A (en) Method for treating and inhibiting gastric and duodenal ulcers
AU710078B2 (en) Bacterial inhibition with an oligosaccharide compound
US4666897A (en) Inhibition of mammalian collagenolytic enzymes by tetracyclines
Vishwanath et al. Tracheobronchial mucin receptor for Pseudomonas aeruginosa: predominance of amino sugars in binding sites
ES2306811T3 (es) Carbohidratos antiinfecciosos.
MXPA96003403A (en) Treatment of diarrhea associated with antibioti
WO1994003184A1 (fr) Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux
AU709149B2 (en) Method for treating and inhibiting gastric and duodenal ulcers
AU705012B2 (en) Treatment of traveller's diarrhea
SK10042003A3 (sk) Použitie látky obsahujúcej Helicobacter pylori
JP2006511497A (ja) ヘリコバクターピロリに対する高親和性レセプターおよびその用途
AU710576B2 (en) Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
US5962423A (en) Treatment of bacterial dysentery
PT655249E (pt) Moenomicina como medicamento para o tratamento de ulceras gastricas
US20050220819A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
JPH11506458A (ja) 旅行者の下痢の処置
JPH07502011A (ja) 免疫抑制性および寛容原性のオリゴ糖誘導体
MXPA98009158A (en) Salt of bismuto de sialiloligosacarido and a metodopara treat and inhibit gastric and duodenal ulceras with the mi
US20060183710A1 (en) Chlamydia oligosaccharides
JP2003535965A5 (fr)
WO2000056343A1 (fr) Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
WO2004065400A1 (fr) Nouveaux epitopes de liaison a helicobacter pylori et utilisation desdits epitopes
Simon Section Review: Biologicals & Immunologicals: Complex carbohydrates in development as human pharmaceuticals
JP2004002239A (ja) TNF−α産生抑制剤
WO1998004272A1 (fr) Oligosaccharides de chlamydiae

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired